Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02871570 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
A Phase 1 study, sponsored by GlycoMimetics Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02871570: Completed Phase 1 study, sponsored by GlycoMimetics Incorporated.
NCT02871570 is a Phase 1 study that has completed, run by GlycoMimetics Incorporated. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02871570, a Phase 1 study, has completed, sponsored by GlycoMimetics Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of hepatic impairment on rivipansel PK and safety.
Interventions
- DRUG Rivipansel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02871570
The ClinicalTrials.gov registry entry for NCT02871570 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlycoMimetics Incorporated, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rivipansel is the first listed.
NCT02871570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02871570 about?
NCT02871570 is a clinical study titled "A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function". The purpose of this study is to determine the effect of hepatic impairment on rivipansel PK and safety.
What is the current status of trial NCT02871570?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-09. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02871570?
The interventions under investigation include: Rivipansel (DRUG).
Who is sponsoring clinical trial NCT02871570?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.